HANK & LIN'S GROUP

1. Wenbin Jin, Ruiyue Zhao, Ran Wang, et al. Theranostic Agent Targeting Bone Metastasis: A Novel [⁶⁸Ga]Ga/[¹⁷⁷Lu]Lu-DOTA-HBED-bisphosphonate. Journal of Medicinal Chemistry2024,67(6):4793-4803

2. Zhao, R., Lv, J., Li, M.et al.First-in-human study of dosimetry, safety and efficacy for [¹⁷⁷Lu]Lu-P15-073: a novel bisphosphonate-based radioligand therapy (RLT) agent for bone metastases. Eur J Nucl Med Mol Imaging(2024). https://doi.org/10.1007/s00259-024-06942-0

3. Jin, W., Wang, R., Zhao, R., Choi, S., Ploessl, K., Alexoff, D., Zhu, L. and Kung, H., 2024. Theranostic Agent Targeting Bone Metastasis: A Novel [68Ga] Ga/[177Lu] Lu-DOTA-HBED-bisphosphonate.Journal of Nuclear MedicineJune 2024,65(supplement 2)241097;

4. Zhao, Ruiyue, Jie Lv, Siran Xu, WenBin Jin, David Alexoff, Karl Ploessl, Lin Zhu, Hank Kung, and Xinlu Wang. "Evaluation safety, dosimetry and efficacy of [177Lu] Lu-P15-073 for therapy of bone metastases."Journal of Nuclear MedicineJune 2024,65(supplement 2)241395;